Form 4: Pfizer Director Acquires Phantom Stock Units

Pfizer Director James Quincey acquired 1,520.801 phantom stock units as deferred compensation, increasing his total beneficial ownership to 71,917.073 units.

Summary

• James Quincey, a Director of Pfizer Inc. (PFE), acquired 1,520.801 phantom stock units.
• The transaction date for this acquisition was September 30, 2025.
• Each phantom stock unit represents one phantom share of common stock.
• The acquisition price per unit was $25.48.
• These units represent deferred director's compensation, including dividend equivalents.
• The units are settled in cash or common stock at the director's election following retirement from the Board of Directors.
• Following this transaction, James Quincey beneficially owns a total of 71,917.073 phantom stock units.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as it reflects a routine compensation event that aligns director interests with shareholders, without any negative implications.

Positives

• The acquisition of phantom stock units aligns the director's long-term interests with those of shareholders, as the value of these units is tied to Pfizer's common stock performance.
• This transaction represents a routine component of director compensation, indicating stable corporate governance practices.

Future Outlook

The phantom stock units will be settled in cash or common stock at the director's election following his retirement from the Board of Directors, indicating a future payout event tied to his tenure.

Industry Context

The use of phantom stock units as a form of deferred compensation for directors is a common practice in large, publicly traded companies across various industries, including pharmaceuticals. It serves to retain talent and align executive and director interests with long-term shareholder value.

Comparison to Industry Standards

• Deferred equity compensation, such as phantom stock units, is a standard practice for director remuneration in major pharmaceutical companies like Johnson & Johnson, Merck, and Bristol Myers Squibb, aiming to foster long-term commitment and align interests.
• The structure, where units are settled upon retirement, is typical for long-term incentive plans designed to retain experienced board members.

Stakeholder Impact

• Shareholders: The transaction reinforces alignment between director compensation and shareholder value, as the units' value is tied to the company's stock performance.
• Employees: No direct impact on general employees is indicated by this director compensation filing.

Next Steps

• The phantom stock units will be settled in cash or common stock upon James Quincey's retirement from the Board of Directors.

Key Dates

Recommendation

This Form 4 filing details a routine acquisition of phantom stock units as part of a director's deferred compensation. It does not present new material information that would fundamentally alter the investment thesis for Pfizer. While it signals continued director alignment, it is not a catalyst for a 'buy' or 'sell' recommendation based solely on this filing. Investors should continue to 'hold' based on broader company fundamentals and market conditions.

Keywords

Pfizer, PFE, James Quincey, Director Compensation, Phantom Stock Units, Insider Transaction, SEC Form 4, Equity Compensation